GlassScriptPhysician profile
Jack T Dinh
NPI 1356366876
$13,211.85
in general payments reported to CMS, 2019-2025
31 companies · $2,152 in 2025
The $2,152 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,752 · 2020: $1,123 · 2021: $2,137 · 2022: $2,115 · 2023: $1,688 · 2024: $2,245 · 2025: $2,152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,071 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,071.28 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,122.05 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Takeda Pharmaceuticals U.S.A., INC. | $1,229.89 | 2019-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,047.22 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $891.23 | 2019-2025 | Tremfya, Stelara, Simponi |
| Gilead Sciences, INC. | $748.28 | 2019-2025 | |
| Pfizer INC. | $744.26 | 2019-2025 | |
| Lilly USA, LLC | $417.40 | 2023-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $396.30 | 2019-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $316.25 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $280.48 | 2024-2025 | Rezdiffra, Resmetirom |
| Nestle Healthcare Nutrition INC. | $271.74 | 2020-2023 | |
| Braintree Laboratories, INC. | $250.73 | 2019-2025 | Sutab, Suflave |
| Genzyme Corporation | $195.96 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $170.66 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $140.71 | 2019-2024 | Rebyota |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $111.36 | 2023-2024 | |
| Ironwood Pharmaceuticals, INC | $101.89 | 2019-2024 | Linzess |
| Qol Medical, LLC | $96.93 | 2019-2023 | Sucraid |
| Phathom Pharmaceuticals, INC. | $92.01 | 2024-2025 | Voquezna |
| Alfasigma USA, INC. | $82.53 | 2020 | |
| Celgene Corporation | $79.78 | 2022 | |
| Vivus LLC | $75.35 | 2022-2025 | Qsymia |
| Ardelyx, INC. | $59.76 | 2023 | Ibsrela |
| Evoke Pharma, INC. | $52.17 | 2021-2025 | |
| Daiichi Sankyo INC. | $50.46 | 2021-2022 | |
| Allergan, INC. | $44.59 | 2019 | |
| Celltrion USA INC. | $42.09 | 2025 | Vegzelma |
| Boston Scientific Corporation | $36.36 | 2022 | |
| Medtronic, INC. | $31.53 | 2022 | |
| Aimmune Therapeutics, INC. | $17.03 | 2025 | Zenpep |
| Redhill Biopharma INC. | $14.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Dinh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.